Ultragenyx | Company Profile - Revenue, Headcount, Tech Stack, Contacts

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company based in Novato, California, founded in 2010. The organization specializes in developing and commercializing therapies for rare and ultra-rare genetic diseases. Established by Dr. Emil D. Kakkis, Ultragenyx seeks to address unmet medical needs for patient populations frequently underserved by larger pharmaceutical firms.

The company is known for innovative treatments, including enzyme replacement therapies, gene therapies, and antisense oligonucleotide therapies. Its product portfolio includes notable therapies such as Crysvita, which achieved significant revenue in 2023. Through strategic acquisitions, Ultragenyx has expanded its pipeline and enhanced capabilities in gene therapy research. The company actively engages with patient communities and caregivers to shape its development priorities, prioritizing corporate responsibility and integrating environmental, social, and governance principles in its operations.